Healthcare / Drug Manufacturers - Specialty & GenericLSE
$3.25
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-4.3M · quality 48.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
6/100
F
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
12/100
SEC 0%
Sin guardar todavía.
Market Cap
$2M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-131.1%
↓Gross Margin
24.8%
↓Debt/Equity
0.70
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2024 · 2 años de histórico normalizado
Revenue CAGR
+74.8%
FCF CAGR
—
FCF margin
-224.6%
FCF / Net income
1.27x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.9M · net income $-3.4M · FCF $-4.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | $1.9M | $1.9M | $82840.00 | $624187.00 |
| Net Income | $-3.4M | $-3.4M | $-4.3M | $-5.7M |
| EBITDA | $-2.8M | $-2.8M | $-3.8M | $-5.5M |
| EPS | -0.01 | -0.01 | -0.02 | -0.03 |
| Gross Margin | 24.8% | 24.8% | -249.7% | -124.8% |
| Operating Margin | -159.9% | -159.9% | -4792.2% | -893.0% |
| Net Margin | -176.6% | -176.6% | -5176.1% | -915.0% |
| Balance Sheet | ||||
| Debt/Equity | 0.70 | 0.70 | 5.37 | 0.22 |
| Current Ratio | 0.87 | 0.87 | — | — |
| Cash Flow | ||||
| Free Cash Flow | $-4.3M | $-4.3M | $-3.2M | $-5.6M |
| Returns | ||||
| ROE | -131.1% | -131.1% | -488.0% | -370.9% |
| Valuation | ||||
| P/B | 437.01 | 437.01 | 12338.55 | 6500.45 |
| Growth & Yield | ||||
| Revenue Growth | 2203.3% | 2203.3% | -86.7% | — |
| EPS Growth | 44.9% | 44.9% | 35.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-84.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.02 → -0.01
Residual
-84.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.